On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer's treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the build up of a protein known as beta amyloid that some think might be one of the possible causes of Alzheimer's disease. While the approval has been applauded by some, it is not without controversy. We will be asking our guests how innovation in the search for treatments of Alzheimer's disease is evolving.
Our guest speakers are Mei Mei Hu, Chief Executive Officer at Vaxxinity, Hans J. Moebius, Chief Medical Officer at Athira Pharma, Raymond J Tesi, Chief Executive Officer and Chief Medical Officer at Inmune Bio, as well as Jerre Stead, Executive Chairman and Chief Executive Officer of Clarivate Plc, and Jonathan Searles, Senior Director on the CNS/Ophthalmology therapy team at Clarivate.
Hosted on Acast. See acast.com/privacy for more information.
